The FDA has approved Fabhalta (iptacopan) for the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria.

The supplemental New Drug Application for the C3G and IC-MPGN indications is supported by data from the phase 3 VALIANT study.

A component of the complement system promotes tumor growth by activating myeloid-derived suppressor cells. Figure 1: Multiple pro-inflammatory mediators in the tumor microenvironment increase the ...

therapeutic designed to reduce liver production of complement component 3 (C3) as a potential therapy for various complement mediated diseases. The company plans to present additional results at a ...

In C3G, overactivation of the alternative complement pathway – part of the immune system – causes deposits of C3 protein to build up in kidney glomeruli, which are a network of blood vessels that ...

ARO-C3 is designed to reduce hepatocyte production of complement C3 as a potential ... stage studies Effects on proteinuria (too much protein in the urine): The mean reduction in spot UPCR was ...

The FDA approved oral iptacopan (Fabhalta; Novartis) to reduce proteinuria in adults with C3 glomerulopathy (C3G), according to a press release from Novartis. 1 Iptacopan is now the first and only FDA ...

In patients with C3G, overactivation of the alternative complement pathway leads to C3 cleavage within the glomeruli ... native kidney C3G who had a urine protein-to-creatinine ratio (UPCR ...

Novartis has a third FDA-approved indication for its oral therapy for complement-mediated diseases – Fabhalta – after getting ...

By silencing C3, investigational ARO-C3 has the potential to treat complement-mediated renal ... stage studies Effects on proteinuria (too much protein in the urine): The mean reduction in spot ...